Last reviewed · How we verify
CSL300
CSL300 is a recombinant human monoclonal antibody that targets the complement system.
CSL300 is a recombinant human monoclonal antibody that targets the complement system. Used for Paroxysmal nocturnal hemoglobinuria (PNH).
At a glance
| Generic name | CSL300 |
|---|---|
| Also known as | Clazakizumab |
| Sponsor | CSL Behring |
| Drug class | Complement inhibitor |
| Target | C5 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
CSL300 works by inhibiting the complement system, specifically the C5 component, to prevent excessive inflammation and tissue damage. This mechanism is thought to be beneficial in treating conditions associated with complement system dysregulation.
Approved indications
- Paroxysmal nocturnal hemoglobinuria (PNH)
Common side effects
- Headache
- Nausea
- Infusion-related reactions
Key clinical trials
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSL300 CI brief — competitive landscape report
- CSL300 updates RSS · CI watch RSS
- CSL Behring portfolio CI